Intravenous immunoglobulin (IVIG), 10% solution for infusion

DRUG2 trials

Sponsors

Biopharma Plasma LLC, Sunnybrook Health Sciences Centre

Conditions

ALSAmyotrophic Lateral SclerosisPrimary Immune Thrombocytopenia

Phase 1

Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)

Active, not recruitingNCT07193953

Sunnybrook Health Sciences CentreALS, Amyotrophic Lateral Sclerosis

Start: 2025-04-15End: 2027-05-30Target: 6Updated: 2026-07-14

Phase 3

Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults

CompletedNCT05422365

Biopharma Plasma LLCPrimary Immune Thrombocytopenia

Start: 2022-07-26End: 2023-12-14Updated: 2024-09-23